New combo therapy shows promise for inoperable liver cancer
NCT ID NCT05532319
First seen Jan 04, 2026 · Last updated May 25, 2026 · Updated 24 times
Summary
This study tested a new combination treatment for people with liver cancer that cannot be removed by surgery. The treatment included chemotherapy delivered directly to the liver, a procedure to block the tumor's blood supply, and two drugs (lenvatinib and tislelizumab). The goal was to see if this approach could help control the cancer and improve survival. The study involved 64 participants and has been completed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, 530021, China
Conditions
Explore the condition pages connected to this study.